Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Veel nieuwe behandelopties verwacht bij behandeling urotheelcelcarcinoom
nov 2019 | Immuuntherapie, Uro-oncologie